Marinus Pharmaceuticals — Company Overview, News & Financial Data
Marinus Pharmaceuticals focuses on innovative therapeutics for epilepsy and neuropsychiatric disorders, advancing neuroscience.
Marinus Pharmaceuticals
Company profile
About Marinus Pharmaceuticals
Marinus Pharmaceuticals (NASDAQ:MRNS) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of epilepsy and other neuropsychiatric disorders. The company's portfolio is centered around its lead candidate, ganaxolone, which is being explored across multiple studies for its potential in treating a range of seizure disorders and neuropsychiatric conditions. Marinus is committed to advancing neuroscience and aiming to provide new treatment options for patients with unmet medical needs. Through ongoing research and development projects, Marinus strives to expand its understanding of neurological diseases and harness the power of its technology to improve patient outcomes.
Snapshot
2003Year founded
172Employees
Pennsylvania, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
United States
Products and/or services of Marinus Pharmaceuticals
- Ganaxolone for CDKL5 deficiency disorder, a rare form of epilepsy in children.
- Development of ganaxolone for status epilepticus, severe seizures that do not respond to first-line treatments.
- Research into ganaxolone for Postpartum Depression, addressing severe mood disorders following childbirth.
- Investigation of ganaxolone in Tuberous Sclerosis Complex, aiming to reduce seizure frequency in this genetic disorder.
- Exploration of ganaxolone for treatment-resistant depression, targeting individuals unresponsive to standard therapies.
- Advancing a proprietary intravenous formulation of ganaxolone for use in hospital settings, enhancing rapid delivery for acute management.
Marinus Pharmaceuticals executive team
- Dr. Scott N. Braunstein M.D.CEO, President & Chairman
- Mr. Steven E. Pfanstiel C.M.A., M.B.A.COO, CFO & Treasurer
- Dr. Joseph Hulihan M.D.Chief Medical Officer
- Dr. Alex Aimetti Ph.D.Chief Scientific Officer
- Ms. Sonya WeigleSenior VP of Investor Relations, Human Resources & Corporate Affairs
- Ms. Martha E. Manning Esq., J. D.Senior VP, General Counsel & Secretary
- Molly CameronDirector of Corporate Communications & Investor Relations
- Dr. Kimberly A. McCormick Pharm.D.Chief Regulatory & Quality Assurance Officer
- Ms. Christina ShaferChief Commercial Officer
- Mr. David CzekaiChief Chemistry, Manufacturing & Controls Officer
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift